Role of mTOR inhibitor in cholangiocarcinoma cell progression

Author：

ISSN： 1792-1074

Source： Oncology Letters, Vol.7, Iss.3, 2014-01, pp. : 854-860

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Role of mTOR in Hematological Malignancies

Current Cancer Therapy Reviews, Vol. 4, Iss. 3, 2008-08 ,pp. : 211-218

Bentham Science Publishers

Access to resources Recommend Favorite

Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma

Molecular Medicine Reports, Vol. 7, Iss. 2, 2013-01 ,pp. : 537-542

Spandidos Publications

Access to resources Recommend Favorite

Mechanisms of mTOR inhibitor resistance in cancer therapy

By Carew Jennifer

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 17-27

Springer Publishing Company

Access to resources Recommend Favorite

Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?

By Walter Thomas Scoazec Jean-Yves Couderc Christophe Forestier Julien Roche Colette Chayvialle Jean-Alain Lombard-Bohas Catherine

Acta Oncologica, Vol. 50, Iss. 5, 2011-06 ,pp. : 731-732

Informa Healthcare

Access to resources Recommend Favorite

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

By Pal Sumanta

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 5-16

Springer Publishing Company

Access to resources Recommend Favorite